Travere Therapeutics Reports Q4 2025 Earnings with Strong Sales Growth and Improved Profitability
Travere Therapeutics (TVTX) reported Q4 2025 earnings with significant growth in net product sales and improved profitability. FILSPARI U.S. net product sales reached $103.3 million in Q4, with total U.S. net product sales hitting $126.6 million, driven by FILSPARI and other products. The company also saw a shift from a net loss to a net income in Q4 compared to the prior-year period.
Topics: earnings financial results net income revenue sales growth